Vantive Announces Agreement to Divest Majority of Hemodialysis Assets and Associated Operations to Rockwell Medical

Vantive says the divestiture sharpens its portfolio focus on home dialysis and critical care.

Rhea-AI Summary

Vantive agreed to sell most of its hemodialysis assets and associated operations to Rockwell Medical (Nasdaq: RMTI) under a definitive agreement.

The transaction covers hemodialysis concentrates, monitors and water treatment systems, along with related consumables and technical services. Ownership of Vantive's manufacturing facility in Medolla, Italy, will transfer to Rockwell Medical upon completion. Vantive's dialyzer portfolio, including Theranova, is excluded.

The companies expect the transaction to close in mid-2027, subject to required regulatory approvals and customary closing conditions.

1 point · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

How the balance works

Positive

• Moderate pointDefinitive divestiture agreement advances Vantive's stated focus on chronic disease management and critical care intervention.

Negative

• Minor pointRequired regulatory approvals remain conditions for the transaction, which is expected to close in mid-2027.

Key Figures

Expected closing: mid-2027

Expected closing

mid-2027

Subject to required regulatory approvals and customary closing conditions

Key Terms

hemodialysis, chronic kidney disease, continuous renal replacement therapy, acute kidney injury, +1 more

5 terms

hemodialysis medical

"assets and associated operations related to Vantive's hemodialysis (HD) business."

Hemodialysis is a medical treatment that cleans a person’s blood when their kidneys can no longer do the job, by routing blood through a machine that filters out waste, excess fluid and adjusts salt levels—think of it as an external, mechanical kidney. It matters to investors because it drives demand for specialized machines, replacement filters, clinics, trained staff and related drugs, and is sensitive to reimbursement rules, treatment volumes and advances that can change costs or market share.

chronic kidney disease medical

"patients living with chronic kidney disease"

Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.

continuous renal replacement therapy medical

"advancing continuous renal replacement therapy for patients"

A hospital procedure that continuously filters a patient’s blood over many hours to replace the work of failing kidneys, similar to a slow, ongoing water purifier for the body. It matters to investors because demand, pricing and reimbursement for the machines, consumable supplies and related drugs affect revenues and costs for medical device makers, hospitals and suppliers tied to critical care and dialysis markets.

acute kidney injury medical

"patients experiencing acute kidney injury in the intensive care unit"

A sudden decline in how well the kidneys remove waste and balance fluids, often developing over hours or days; think of it like an engine that abruptly loses power and can’t filter efficiently. It matters to investors because it can drive higher medical costs, alter clinical trial results, trigger regulatory scrutiny, lead to drug label changes or recalls, and affect revenue and liability for healthcare and life sciences companies.

dialyzer medical

"Vantive's dialyzer portfolio, including the Theranova dialyzer"

A dialyzer is a medical device—often a single-use cartridge containing thousands of hollow polymer fibers—that performs the blood-cleaning function of the kidney during a hemodialysis treatment. Blood flows inside the fibers while a specially formulated fluid (dialysate) flows outside them; a semipermeable membrane in the fibers allows waste molecules and excess water to pass from the blood into the dialysate while retaining blood cells and larger proteins. It is used together with a dialysis machine and vascular access; the dialyzer itself does not pump blood or replace the need for a trained operator and regulatory clearance for medical use.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Sharpens Vantive's Focus on Home Dialysis and Critical Care

DEERFIELD, Ill., Nov. 3, 2026 /PRNewswire/ -- Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, today announced that it has entered into a definitive agreement with Rockwell Medical, Inc. (Nasdaq: RMTI) to divest the majority of the assets and associated operations related to Vantive's hemodialysis (HD) business. This transaction advances Vantive's evolution, with a more focused, growth-oriented portfolio centered around chronic disease management and critical care intervention.

Vantive is building on its legacy of innovation by prioritizing investment in the areas where it is uniquely positioned to make a meaningful difference for patients and care teams. Throughout its history, Vantive has pioneered therapies that redefined kidney care – from making home dialysis broadly available to patients living with chronic kidney disease, to advancing continuous renal replacement therapy for patients experiencing acute kidney injury in the intensive care unit (ICU). Today, Vantive is making dialysis easier to start, manage and sustain by enabling more patients to receive therapy at home, while selectively expanding its kidney care platform to advance a more integrated approach to addressing organ failure in the ICU setting.

"We see a significant opportunity to close the gap between the care we know is possible and the care patients and providers experience today," said Chris Toth, CEO of Vantive. "This announcement brings Vantive's ambition into sharper focus. We are applying our expertise and scale to make care easier to access, simpler to deliver and more effective for the people who rely on our therapies. Whether that care happens at home over many years or in the ICU during a critical moment, our goal is to help ensure the right therapy can be delivered at the right time, with greater confidence for care teams."

Positioning HD for Continued Growth with Rockwell Medical

Under the terms of the agreement, Rockwell Medical will acquire Vantive's hemodialysis concentrates, HD monitors, and water treatment systems, together with related consumables and technical services.

Toth continued, "We are confident Rockwell Medical is well positioned to support the continued growth and development of this important therapy. With a singular focus on hemodialysis, Rockwell Medical is deeply committed to accelerating the progress that our team has made. As a result, we believe the combined business will benefit from increased investment, creating new opportunities for innovation and growth. We are committed to working together through the transition to help ensure continuity of care and reliable access to the products, services and support that patients and care providers depend on."

"This transaction represents an exciting opportunity to build on the strong foundation established by the Vantive team over many decades," said Mark Strobeck, Ph.D., President and CEO of Rockwell Medical. "As a company singularly focused on hemodialysis, we are committed to advancing the quality, reliability and customer support that providers and patients depend on every day. We believe this portfolio has significant opportunities for continued growth, and we look forward to bringing together complementary capabilities to better serve dialysis providers worldwide and further strengthen our position in the global hemodialysis market."

The transaction is expected to close in mid-2027, subject to receipt of required regulatory approvals and satisfaction of other customary closing conditions. Upon the completion of the transaction, ownership of Vantive's manufacturing facility in Medolla, Italy will transfer to Rockwell Medical to support capacity and the continued development of the global HD business. Vantive's dialyzer portfolio, including the Theranova dialyzer, which enables HDx therapy (expanded hemodialysis), is not included in the transaction.

Perella Weinberg Partners LP and Barclays are acting as financial advisors, and Kirkland & Ellis LLP is acting as legal counsel to Vantive. Aquilo Partners, L.P. is acting as exclusive financial advisor and Gibson Dunn & Crutcher LLP is acting as legal counsel to Rockwell Medical.

Vantive, HDx, and Theranova are trademarks of Vantive Health LLC or its affiliates.

About Vantive

Vantive is a vital organ therapy company on a mission to extend lives and expand possibilities for patients and care teams globally. For 70 years, our team has driven meaningful innovations in kidney care. Today, Vantive's people, solutions and services deliver over 1 million touchpoints each day to patients around the world. As we build on our legacy, we are focused on elevating the dialysis experience through digital solutions and advanced services, while looking beyond kidney care and investing in transforming vital organ therapies. Our goal is to provide therapies that fit more easily into providers' practices and patients' lives. Greater flexibility and efficiency in therapy administration for care teams, and longer, fuller lives for patients— that is what Vantive aspires to deliver. To learn more, visit www.vantive.com and follow us on LinkedIn, X, Facebook, Instagram and YouTube.

About Rockwell Medical

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient's home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work® four years in a row (2023-2026) and named Fortune Best Workplaces in Manufacturing & Production™ three years in a row (2024-2026), Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions™. For more information, visit www.rockwellmed.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/vantive-announces-agreement-to-divest-majority-of-hemodialysis-assets-and-associated-operations-to-rockwell-medical-302927735.html

SOURCE VANTIVE US HEALTHCARE LLC

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Rockwell Medical buying from Vantive?

Rockwell Medical will acquire most of Vantive's hemodialysis assets and associated operations, including concentrates, monitors, water treatment systems, related consumables and technical services. Vantive's Medolla, Italy, manufacturing facility will transfer upon completion. The dialyzer portfolio, including Theranova, is excluded.

When is Vantive's sale to Rockwell Medical expected to close?

The transaction is expected to close in mid-2027, subject to required regulatory approvals and satisfaction of other customary closing conditions.